雅克科技(002409.SZ):擬與大基金等向江蘇先科增資17.45億元
格隆匯8月29日丨雅克科技(002409.SZ)公佈,公司擬與國家集成電路產業投資基金二期股份有限公司等16家增資方,以17.45億元認購交割後江蘇先科充分稀釋基礎上70.7868%股權,對應新增註冊資本7.27億元,超出部分10.18億元計入江蘇先科資本公積。增資款主要用於江蘇先科的光刻膠和半導體領域前驅體等相關材料的研發及生產。本次交易完成後,江蘇先科股權結構將由公司100%持股調整為公司持股33.07%,公司仍對江蘇先科保持控制權。
其中,各增資方本次增資金額對應江蘇先科新增註冊資
本及計入資本公積金額如下:

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.